Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> Maltotetraose [34612-38-9]

Maltotetraose [34612-38-9]

Imprimer Imprimer
Identifiez-vous

Référence HY-N2464-25mg

Conditionnement : 25mg

Marque : MedChemExpress


Description

Maltotetraose can serve as a substrate for enzyme-linked assays to measure amylase activity in biological fluids. Maltotetraose has oral active, and reduces TNF-α-induced inflammatory responses by inhibiting NF-κB activity and decreasing ICAM-1 expression. Maltotetraose also inhibits PDGF-induced vascular smooth muscle cell migration and neovascularization. Additionally, Maltotetraose derivatives can function as probes for detecting bacterial infections by targeting the maltodextrin transporter. With good long-term safety, Maltotetraose holds promise for research in atherosclerosis-related diseases[1][2][3][4].

IC50 & Target

Human Endogenous Metabolite

 

In Vitro

Maltotetraose (20-40 μM, 30 min) suppresses NF-κB activation and ICAM-1 expression, potentially aiding in the early prevention of atherosclerosis[2].
Maltotetraose (20 μM, 30 min) inhibits PDGF-induced vascular smooth muscle cell migration, suggesting a potential role in atherosclerosis prevention[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Maltotetraose Related Antibodies

Western Blot Analysis[2]

Cell Line: MOVAS-1 mouse vascular smooth muscle cells
Concentration: 20-40 μM
Incubation Time: 30 min (Cells were pretreated with Maltotetraose (20-40 μM) for 30 minutes, followed by TNF-α (10 ng/mL) stimulation for 3-8 hours)
Result: Inhibited the phosphorylation of NF-κB-related protein.

RT-PCR[2]

Cell Line: MOVAS-1 mouse vascular smooth muscle cells
Concentration: 20-40 μM
Incubation Time: 30 min (Cells were pretreated with Maltotetraose (20-40 μM) for 30 minutes, followed by TNF-α (10 ng/mL) stimulation for 3-8 hours)
Result: Significantly decreased ICAM-1 mRNA levels.

Cell Migration Assay [2]

Cell Line: MOVAS-1 mouse vascular smooth muscle cells
Concentration: 20 μM
Incubation Time: 30 min (Cells were pretreated with Maltotetraose (20 μM) for 30 minutes, followed by PDGF (20 ng/mL) stimulation for 6-7 days)
Result: Significantly inhibited PDGF-induced vascular smooth muscle cell migration and new blood vessel formation in aortic ring explants.
In Vivo

Maltotetraose (10% in diet or 5,000 mg/kg via p.o., once daily for 90 days) dose not induce significant toxicity, suggesting good long-term safety[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar rats[3]
Dosage: Dietary group: 10% (equivalent to 6,818 mg/kg/day in males, 7,464 mg/kg/day in females); Gavage group: 1,000, 3,000, or 5,000 mg/kg/day
Administration: Dietary intake or oral gavage (p.o.), Once daily for 90 consecutive days
Result: Sid not cause mortality or severe adverse effects in rats over 90 days.
Reduced food intake but no significant body weight differences (The 5,000 mg/kg/day gavage group).
Masse moléculaire

666.58

Formule

C24H42O21
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

OC[C@@H](O[C@H](O[C@@]([C@H](O)CO)(12)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]1O)[C@@]1(12)O[C@H]2O[C@@H]([C@@H](O[C@@]3(12)O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO
Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvant et solubilité
In Vitro: 

H2O : 125 mg/mL (187.52 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.5002 mL 7.5010 mL 15.0019 mL
5 mM 0.3000 mL 1.5002 mL 3.0004 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (150.02 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Pureté et documentation
Références